UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 11.

Safroneeva, E; Vavricka, S R; Fournier, N; Pittet, V; Peyrin-Biroulet, L; Straumann, A; Rogler, G; Schoepfer, A M; Braegger, C; Swiss IBD Cohort Study Group (2015). Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Alimentary Pharmacology & Therapeutics, 42(8):977-989.

Safroneeva, E; Vavricka, S; Fournier, N; Seibold, F; Mottet, C; Nydegger, A; Ezri, J; Straumann, A; Rogler, G; Schoepfer, A M; Braegger, C; Swiss IBD Cohort Study Group (2015). Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Alimentary Pharmacology & Therapeutics, 42(5):540-548.

Vavricka, S R; Bentele, N; Scharl, M; Rogler, G; Zeitz, J; Frei, P; Straumann, A; Binek, J; Schoepfer, A M; Fried, M (2012). Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflammatory Bowel Diseases, 18(8):1523-1530.

Vavricka, S R; Spigaglia, S M; Rogler, G; Pittet, V; Michetti, P; Felley, C; Mottet, C; Braegger, C P; Rogler, D; Straumann, A; Bauerfeind, P; Fried, M; Schoepfer, A M (2011). Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases, 18(3):496-505.

Vavricka, S R; Schoepfer, A M; Bansky, G; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Scharl, M; Seibold, F; Straumann, A; Michetti, P (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases, 17(7):1530-1539.

Schoepfer, A M; Vavricka, S R; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Seibold, F; Straumann, A; Michetti, P (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory Bowel Diseases, 16(6):933-938.

Nichita, C; Stelle, M; Vavricka, S; El-Wafa Ali, A; Ballabeni, P; de Saussure, P; Straumann, A; Rogler, G; Michetti, P (2010). Clinical experience with Adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion, 81(2):78-85.

Schoepfer, A M; Beglinger, C; Straumann, A; Trummler, M; Vavricka, S R; Bruegger, L E; Seibold, F (2010). Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology, 105(1):162-169.

Voegtlin, M; Vavricka, S R; Schoepfer, A M; Straumann, A; Voegtlin, J; Rogler, G; Ballabeni, P; Pittet, V; Buser, A; Fried, M; Beglinger, C (2010). Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. Journal of Crohn's and Colitis, 4(6):642-648.

Yousefi, S; Gold, J A; Andina, N; Lee, J J; Kelly, A M; Kozlowski, E; Schmid, I; Straumann, A; Reichenbach, J; Gleich, G J; Simon, H U (2008). Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nature Medicine, 14(9):949-953.

Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab-Monotherapie versus Kombinationstherapie mit Immunmodulatoren : Aktuelle Therapieempfehlungen einer Schweizer Expertengruppe. Medical Journal (TMJ), (1):32-34.

This list was generated on Tue Jul 25 21:26:42 2017 CEST.